Soleno Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those associated with genetic and metabolic disorders
The company is committed to addressing significant unmet medical needs by advancing its proprietary treatment candidates through clinical trials. With an emphasis on leveraging cutting-edge science and research, Soleno aims to bring novel solutions to patients suffering from conditions like Prader-Willi syndrome, thereby enhancing their quality of life and overall health outcomes.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline) extended-release tablets.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming to boost U.S. manufacturing and reduce reliance on global suppliers, new auto tariffs were introduced on Wednesday, which will go into effect from April 3.
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc.
